Fuse Oncology Launches FuseRx Prescribing and Treatment Platform for Radiation Oncology

Jul 21, 2026
Fuse Oncology has launched FuseRx, a prescribing and treatment-intent platform for radiation oncology, debuting at the 2026 AAPM Annual Meeting in Vancouver. The system integrates prescribing, simulation, and treatment planning into one guided workflow with built-in validation and pathway support.

Fuse Oncology has launched FuseRx, a prescribing and treatment-intent solution for radiation oncology, announced in a press release. The system is being introduced at the 68th AAPM Annual Meeting and Exhibition in Vancouver.

FuseRx serves as a central component of the Fuse platform, linking consultation, simulation, planning, and treatment within a single structured workflow. It enables physicians to create a complete treatment plan, including simulation orders, prescriptions, and target goals, using configurable templates and a validation engine with safety checks and audit tracking.

The platform supports clinical pathways at the point of prescribing, incorporating both local protocols and published evidence-based guidelines. Integration with the American College of Radiation Oncology's ACROPath pathways provides clinicians with decision support during treatment planning, aimed at maintaining consistency while preserving physician discretion.

FuseRx operates alongside existing Fuse products, including S!GNAL and FuseDocs, within a unified system that shares patient data and workflow context from consultation onward. Attendees of AAPM 2026 can view the platform demonstration at booth #610.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Guide
Specialist Ambient Medical Scribe Vendors

Specialist Ambient Medical Scribe Vendors

AI scribes that turn medical consultations into draft clinical notes

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.